Uses of Anacare: - Breast cancer Oral Advanced or locally advanced breast cancer, Adjuvant treatment in early breast cancer Adult: In postmenopausal women: 1 mg daily. Adjuvant treatment may be continued for up to 5 yr. Hepatic Impairment Mild-to-moderate impairment or stable hepatic cirrhosis: Dose adjustment not necessary Severe hepatic impairment: Not studied

Hormonal Chemotherapy

The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.

How to use Anastrozole: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Anastrozole may be taken with or without food, but it is better to take it at a fixed time. Administration: Efficacy decreased by oestrogens. Plasma concentrations decreased by tamoxifen. Adult Dose: Moderate or severe hepatic impairment, hyperlipidaemias. Laboratory test for menopause if status is doubtful. Bone mass density test should be conducted at the start of the therapy and at regular intervals thereafter. Lactation: Unknown whether drug is excreted in milk; not recommended given potential for serious adverse reactions in nursing infants Renal Dose: Anastrozole prevents conversion of androstenedione to estrone and testosterone to oestradiol by inhibiting aromatase, thus leading to significantly reduced serum oestradiol concentrations.

Pregnancy. Hypersensitivity, premenopausal women.

Patients with severe renal impairment (Creatinine clearance less than 20 mL/min), patients with moderate to severe hepatic disease and known hypersensitivity to anastrozole or to any of the excipients. Oestrozen-containing therapies should not be co-administered with anastrazole as they would negate its pharmacological action.

Common - Headache - Musculoskeletal (bone, muscle or joint) pain - Nausea - Osteoporosis - Skin rash - Weakness

Anastrozole is contraindicated in pregnant and lactating women.

Precaution: Breast cancer, Ovulation induction

There is limited clinical experience of overdose of Anastrozole. There are no reports where a patient has taken a dose in excess of 60 mg. No toxicity was observed and no clinically relevant adverse effects have been seen.

Store in a cool & dry place, protected from light and moisture. Keep out of reach of children.

Hormonal Chemotherapy

May be taken with or without food.

>10% Hot flashes (12-36%),Vasodilation (25-36%),Fatigue (19%),Mood disturbances (19%),Nausea and vomiting (19%),Weakness (16-19%),Arthritis (17%),Pain (17%),Arthralgia (2-15%),Pharyngitis (14%),Depression (13%),Hypertension (2-13%),Bone pain (11%),Increased cough (11%),Osteoporosis (11%),Rash (8-11%) 1-10% Accidental injury (10%),Back pain (10%),Fracture (10%),Headache (10%),Insomnia (10%),Peripheral edema (10%),Dyspnea (8-10%),Abdominal pain (9%),Infection (9%),Lymphedema (9%),Diarrhea (8-9%),Constipation (7-9%),Breast pain (8%),Dizziness (8%),Urinary tract infection (8%),Chest pain (7%),Dyspepsia (7%),Paresthesia (5-7%),Anxiety (6%),Cataracts (6%),Flu syndrome (6%),Sinusitis (6%),Vulvovaginitis (6%),Xerostomia (6%),Breast neoplasm (5%),Bronchitis (5%),Cyst (5%),Diaphoresis (5%),Neoplasm (5%),Vaginal bleeding (5%),Fractures of spine, hip, or wrist (4%),Ischemic cardiovascular disease (4%),Vaginal hemorrhage (4%),Vaginitis (4%),Leukorrhea (3-4%),Deep vein thrombosis (2%),Endometrial cancer (intact uterus at baseline) (2%),Ischemic cerebrovascular event (2%),Weight gain (2%),Lethargy (1%)